Excessive Medical Spending: Facing the Challenge
Norman J. Temple, Andrew Thompson
Radcliffe Publishing, 2007 - Medical - 195 pages
This work contains a Foreword by Merrill Goozner, Author and Director, Integrity in Science, Center for Science and the Public Interest, Washington DC. This book exposes why healthcare costs have been rapidly increasing and includes a close examination of over-priced drugs. It contains a detailed explanation of how the drug industry takes billions of dollars from society each year and proposes radical new ideas to reign in excessive spending on medicine. Based on the latest research, its unique approach takes into account the pharmaceutical industry, healthcare policy and society to offer a wide ranging account. It is invaluable for all healthcare professionals, especially managers and doctors and nurses with budgetary responsibilities. It will also be useful for researchers, policy makers and shapers, pharmaceutical company executives and general readers with an interest in medical expenditure. "While most discussions about the fiscal problems caused by aging societies have focused on pensions and income security, the more serious landmine in the road ahead is health-care finance, which will be in full-blown crisis sometime early in the next decade. That's why this book is timely. Until we learn to talk openly and honestly about what constitutes good health, good health care, and the best and most cost-effective way of achieving both, we'll never have an affordable health-care system." - Merrill Goozner, in the Foreword.
What people are saying - Write a review
We haven't found any reviews in the usual places.
The nuts and bolts of medical research
two paradigms in conflict
how drug companies manipulate
Potential savings from therapeutic substitution of 10 of Canadas
is the net being thrown too wide?
benefits versus costs
Other editions - View all
000 per QALY accessed November 11 ACE inhibitors advertising American analysis antibiotics approval associated Available benefit breast cancer Canada Canadian cancer screening cardiovascular cervical Chapter cholesterol clinical trials CNBSS COIs conflict of interest cost limit cost-effectiveness death developed doctors dollars drug companies DTCA effective estimated ethical evaluation evidence expenditures expensive factors funding guidelines Health Canada health promotion healthcare heart disease Heart Protection Study hypertension impact increase industry’s inhibitors investigators JAMA journals Lancet Lexchin lifestyle major mammography medical education medical interventions medicine million mortality NSAIDs nutrition patients Pharmacare pharmaceutical companies pharmaceutical industry physicians placebo potential practice pravastatin prescribing prescription drugs prevention problem profit prostate cancer public health QALY randomized reduce reference-based pricing regulation regulatory risk of CHD spending SSRIs statins strategy testing therapeutic therapy treatment tumors Vioxx